Australia's most trusted
source of pharma news
Thursday, 02 May 2024
Posted 16 April 2024 AM
US-based Seaport Therapeutics has raised $100 million in an oversubscribed Series A round to progress neuropsychiatric drugs based on an Aussie invention.
The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health, which announced the launch of the subsidiary in January.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.